PortfoliosLab logoPortfoliosLab logo
OPRX vs. NICE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

OPRX vs. NICE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in OptimizeRx Corporation (OPRX) and NICE Ltd. (NICE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, OPRX achieves a -47.72% return, which is significantly lower than NICE's -11.77% return. Over the past 10 years, OPRX has outperformed NICE with an annualized return of 18.64%, while NICE has yielded a comparatively lower 4.49% annualized return.


OPRX

1D
2.07%
1M
21.40%
6M
-51.29%
YTD
-47.72%
1Y
-49.53%
3Y*
-24.61%
5Y*
-35.05%
10Y*
18.64%

NICE

1D
1.92%
1M
13.24%
6M
-14.80%
YTD
-11.77%
1Y
-35.59%
3Y*
-21.22%
5Y*
-17.19%
10Y*
4.49%
*Multi-year figures are annualized to reflect compound growth (CAGR)

OPRX vs. NICE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
OPRX
OptimizeRx Corporation
-47.72%152.26%-66.04%-14.82%-72.95%99.33%203.41%-6.38%598.73%93.83%
NICE
NICE Ltd.
-11.77%-33.44%-14.87%3.75%-36.66%7.07%82.75%43.38%17.73%33.92%

Correlation

The correlation between OPRX and NICE is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Jul 13, 2007

0.13

The correlation between OPRX and NICE shifts across timeframes, from 0.13 (all time) to 0.32 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

OPRX:

$120.28M

NICE:

$5.84B

EPS

OPRX:

$0.36

NICE:

$8.52

PE Ratio

OPRX:

17.87

NICE:

11.70

PEG Ratio

OPRX:

0.03

NICE:

0.35

PS Ratio

OPRX:

1.14

NICE:

2.06

PB Ratio

OPRX:

0.93

NICE:

1.64

Total Revenue (TTM)

OPRX:

$107.35M

NICE:

$3.01B

Gross Profit (TTM)

OPRX:

$70.86M

NICE:

$1.98B

EBITDA (TTM)

OPRX:

$16.55M

NICE:

$841.27M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

OPRX vs. NICE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OPRX
OPRX Risk / Return Rank: 1919
Overall Rank
OPRX Sharpe Ratio Rank: 1515
Sharpe Ratio Rank
OPRX Sortino Ratio Rank: 1717
Sortino Ratio Rank
OPRX Omega Ratio Rank: 1818
Omega Ratio Rank
OPRX Calmar Ratio Rank: 2020
Calmar Ratio Rank
OPRX Martin Ratio Rank: 2222
Martin Ratio Rank

NICE
NICE Risk / Return Rank: 1414
Overall Rank
NICE Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
NICE Sortino Ratio Rank: 1515
Sortino Ratio Rank
NICE Omega Ratio Rank: 1313
Omega Ratio Rank
NICE Calmar Ratio Rank: 1515
Calmar Ratio Rank
NICE Martin Ratio Rank: 1616
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OPRX vs. NICE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for OptimizeRx Corporation (OPRX) and NICE Ltd. (NICE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


OPRXNICEDifference
Sharpe ratioReturn per unit of total volatility

+0.10

Sortino ratioReturn per unit of downside risk

+0.12

Omega ratioGain probability vs. loss probability

0.91

0.87

+0.04

Calmar ratioReturn relative to maximum drawdown

-0.66

-0.76

+0.10

Martin ratioReturn relative to average drawdown

-1.04

-1.20

+0.16

OPRX vs. NICE - Sharpe Ratio Comparison

The current OPRX Sharpe Ratio is -0.66, which is comparable to the NICE Sharpe Ratio of -0.76. The chart below compares the historical Sharpe Ratios of OPRX and NICE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

OPRX vs. NICE - Drawdown Comparison

The maximum OPRX drawdown since its inception was -99.32%, which is greater than NICE's maximum drawdown of -93.23%. Use the drawdown chart below to compare losses from any high point for OPRX and NICE.


Loading charts...

Drawdown Indicators


OPRXNICEDifference

Max Drawdown

Largest peak-to-trough decline

-99.32%

-93.23%

-6.09%

Max Drawdown (1Y)

Largest decline over 1 year

-79.06%

-51.19%

-27.87%

Max Drawdown (3Y)

Largest decline over 3 years

-79.06%

-68.21%

-10.85%

Max Drawdown (5Y)

Largest decline over 5 years

-96.10%

-73.60%

-22.50%

Max Drawdown (10Y)

Largest decline over 10 years

-96.10%

-73.60%

-22.50%

Current Drawdown

Current decline from peak

-93.46%

-68.34%

-25.12%

Average Drawdown

Average peak-to-trough decline

-60.69%

-35.27%

-25.42%

Ulcer Index

Depth and duration of drawdowns from previous peaks

49.95%

32.47%

+17.48%

Volatility

OPRX vs. NICE - Volatility Comparison

OptimizeRx Corporation (OPRX) has a higher volatility of 15.60% compared to NICE Ltd. (NICE) at 10.16%. This indicates that OPRX's price experiences larger fluctuations and is considered to be riskier than NICE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


OPRXNICEDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.60%

10.16%

+5.44%

Volatility (6M)

Calculated over the trailing 6-month period

54.82%

42.52%

+12.30%

Volatility (1Y)

Calculated over the trailing 1-year period

79.01%

51.48%

+27.53%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

76.06%

39.92%

+36.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

114.59%

33.27%

+81.32%

Dividends

OPRX vs. NICE - Dividend Comparison

Neither OPRX nor NICE has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
NICE
NICE Ltd.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.14%0.76%0.91%
OPRX
OptimizeRx Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

OPRX vs. NICE - Financials Comparison

This section allows you to compare key financial metrics between OptimizeRx Corporation and NICE Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
19.84M
766.53M
(OPRX) Total Revenue
(NICE) Total Revenue
Values in USD except per share items

OPRX vs. NICE - Profitability Comparison

The chart below illustrates the profitability comparison between OptimizeRx Corporation and NICE Ltd. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%75.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
75.3%
64.4%
Portfolio components
OPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, OptimizeRx Corporation reported a gross profit of 14.93M and revenue of 19.84M. Therefore, the gross margin over that period was 75.3%.

NICE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported a gross profit of 493.46M and revenue of 766.53M. Therefore, the gross margin over that period was 64.4%.

OPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, OptimizeRx Corporation reported an operating income of 396.00K and revenue of 19.84M, resulting in an operating margin of 2.0%.

NICE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported an operating income of 126.41M and revenue of 766.53M, resulting in an operating margin of 16.5%.

OPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, OptimizeRx Corporation reported a net income of -495.00K and revenue of 19.84M, resulting in a net margin of -2.5%.

NICE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, NICE Ltd. reported a net income of 46.69M and revenue of 766.53M, resulting in a net margin of 6.1%.


Frequently Asked Questions


OPRX and NICE have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OPRX has higher volatility (15.60%) compared to NICE (10.16%). In terms of maximum drawdown, OPRX dropped -99.32% vs NICE's -93.23%.

OPRX currently has the higher Sharpe Ratio (-0.66 vs -0.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for OPRX and NICE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer